Compare Global X Robotics and Artificial Intelligence ETF (BOTZ) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robotics and Artificial Intelligence ETF vs Smith & Nephew plc — how do they compare? Global X Robotics and Artificial Intelligence ETF trades at $37.76, while Smith & Nephew plc trades at $30.05 (market cap $12.50B). The key difference: Smith & Nephew plc pays a 2.64% dividend while Global X Robotics and Artificial Intelligence ETF pays none, and Global X Robotics and Artificial Intelligence ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| BOTZ | SNN | |
|---|---|---|
52-Week High | $41.63 | $38.70 |
52-Week Low | $31.99 | $28.73 |
Market Cap | — | $12.50B |
Sector | — | Health |
Enterprise Value | — | $15.53B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOTZ trades at $37.61, up 1.81% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF focuses on robotics and AI, offering exposure to global leaders in automation. Recent news highlights its role in the expanding AI and robotics theme, with comparisons to peers like ARKQ and ROBO. A small dividend is scheduled for 2026.
Outlook is positive due to growth in AI and robotics adoption, but risks include high valuation sensitivity and sector competition. Investors should weigh the thematic growth potential against market volatility and the ETF's expense structure.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Robotics and Artificial Intelligence ETF
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Read more on BOTZ →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
